After swirling rumours of a potential takeover of Gilgamesh Pharmaceuticals, AbbVie has entered into an agreement to acquire Gilgamesh’s lead asset bretisilocin (GM-2505) for US$1.2 B. Bretisilocin is a potential best-in-class psychedelic compound currently in Phase II development for the treatment of patients with moderate-to-severe major depressive disorder (MDD). Following the deal, Gilgamesh will spin off a new entity known as Gilgamesh Pharma to hold its employees and other neurology programmes. The purchase of bretisilocin marks yet another move by AbbVie in the CNS space as it attempts to expand its neurology pipeline.